Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research CouncilVIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral DrugsLexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (“NRC”). |